ClinicalTrials.gg
Enrolling by invitationNCT06725095Updated Jun 4, 2025

Effects of Enamel Matrix Derivative in the Treatment of Peri-implant Mucositis

An interventional study of Placebo gel and Enamel Matrix Proteins Derivative in Mucositis and Peri Implant Mucositis, sponsored by University of Catania. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by University of Catania · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Mucositis with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Mucositis · Italy.

Planned enrollment
10th of 23
54 · median 52
Started
2024
with 1 other
No phase
19 of 29
3 open now
Registered
25th of 29
by date
Lead sponsor
3 of 29
University of Catania

Among the 29 studies in Mucositis with a site in Italy, this one is the 10th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2024, is one of 19 with no phase, and was the 25th registered.

Mucositis

265 studies on the registry are indexed under Mucositis; 34 are open to participants now.

Browse Mucositis studies →

Open to participants now

3 of the 29 studies in Mucositis with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 21 Mucositis studies recruiting now, 13 (62%) set no upper age limit and 7 (33%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Mucositis with a site in Italy, or all of them as a file.
02

Study summary

To evaluate the naturally occurring peri-implant mucositis (PM) treatment by means of non-surgical sub-marginal peri-implant instrumentation (NSPI) with or without use of enamel matrix protein derivative (EMD). Specifically, the primary outcome of the present study compared the efficacy of NSPI +EMD with respect to NSPI and placebo in the treatment of PM at 6 months follow-up by means of BOP reduction. The secondary outcome evaluated the influence of possible predictors on the BOP changes among all follow-up sessions.

Read the detailed description

Patients (n° 54) with Implants affected by PM were randomly assigned to test (NSMD+EMD) or control procedures (NSMD + placebo). At baseline, 1, 3, 6 months, full-mouth plaque score (FMPS), full-mouth bleeding score (FMBS), probing depth (PD), bleeding on probing (BOP), modified gingival index (mGI), and modified plaque index (mPlI) will assessed as well as levels of periodontal bacteria such as Aggregatibacter Actynomycencomitans, Porphyromonas Gingivalis, Tannerella Forsythia and Treponema Denticola. The BOP reduction was set as a primary outcome and the patient was considered statistical unit. Data were analysed to assess BOP reduction at a 6-month follow-up and to identify significant predictors of implant-site BOP through mixed generalized linear regression.

03

Conditions studied

  • Mucositis
  • Peri Implant Mucositis

Browse trials for

Keywords

  • Enamel matrix derivative
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥18 years old;
  • implants with smooth necks supporting cemented or screw-retained single-unit crowns with at least one BOP-positive site (Berglundh et al., 2018),
  • implants placed in both maxilla and mandible
  • patients with gingivitis or treated periodontitis with the absence of residual PD ≥5 mm
  • presence at least of 2 mm of keratinized mucosa (KT) at implant sites

Exclusion criteria

Exclusion Criteria:

  • presence of systemic diseases;
  • pregnancy or lactating;
  • use of inflammatory drugs or antibiotics within 3 months prior to study recruitment;
  • implants with modified (i.e., micro-rough) necks;
  • interproximal open contacts between implant restoration and adjacent teeth; peri-implantitis (Berglundh et al., 2018)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Comparator: non-surgical sub-marginal peri-implant instrumentation (NSPI) with placebo gel

    Patients received a one-session of non-surgical sub-marginal peri-implant instrumentation (NSPI) with placebo

    Other: Placebo gel

  • Active comparator
    non-surgical sub-marginal peri-implant instrumentation (NSPI) with EMD

    Patients received a one-session of non-surgical sub-marginal peri-implant instrumentation (NSPI) with EMD

    Other: Enamel Matrix Proteins Derivative

Interventions

  • OtherPlacebo gel

    Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo gel

  • OtherEnamel Matrix Proteins Derivative

    Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of non-surgical treatment plus Enamel Matrix Proteins Derivative

06

What researchers measure

Primary outcomes

  1. Bleeding on probing (BOP) changes

    The number of implants presenting with complete absence of BOP or implants with limited extent of BOP (≤1 spot/implant-the presence of a single spot)

    Time frame: 6-months

Secondary outcomes

  1. Probing pocket depth (PPD) changes

    Changes in PPD

    Time frame: 6-months

  2. Full mouth plaque score (FMPS) % changes

    Full mouth plaque score (FMPS) % changes

    Time frame: 6-months

  3. Full mouth bleeding score (FMBS) % changes

    Changes in FMBS

    Time frame: 6-months

  4. Plaque at implant sites according to modified gingival index (mGI) changes score

    Changes in mGI 0-4 score

    Time frame: 6-months

  5. Plaque at implant sites according to modified plaque index (mPlI) changes score

    Changes in mPlI 0-4 score

    Time frame: 6-months

  6. Patient-Reported Outcome Measures (PROMs)

    Patient-Reported Outcome Measures (PROMs) Were evaluated PROMs such as the number of abscesses, systemic complications, gingival recession, excessive bleeding, allergic effects, systemic impacts and related drug side effects

    Time frame: 6-months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Pubmed

Supporting information: Study protocol

Time frame: 6 months

Access criteria: pubmed databse

Data sharing details ↗ · pubmed.ncbi.nlm.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Feb 2025, 1 month.

Of 67 non-industry interventional studies with no phase under Mucositis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 26. This study's 1 month is below that.

Counting every sponsor, half of 70 studies reached it within 12 months; a quarter within 6 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 10, 2024
StartActual
Dec 5, 2024
Primary completionActual
Feb 1, 2025
CompletionEst.
Jun 5, 2025
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06725095
Lead sponsor
University of Catania
Responsible party
Gaetano Isola (Associate Professor, University of Catania) — Principal investigator
First posted
Dec 10, 2024
Start date
Dec 5, 2024
Primary completion
Feb 1, 2025
Completion
Jun 5, 2025 (estimated)
Last update
Jun 4, 2025

Study contacts

Gaetano Isola, DDS
principal investigator · University of Catania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion